- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Precigen Inc (PGEN)
Precigen Inc stock price live, this page displays NASDAQ PGEN stock exchange data. View the PGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Precigen Inc real time stock price chart below.
What Is the Precigen Inc Stock Price Today?
The Precigen Inc stock price today is 4.080.
What Is the Stock Symbol for Precigen Inc?
The stock symbol for Precigen Inc is ""PGEN.""
What Stock Exchange Does Precigen Inc Trade On?
Precigen Inc is listed and trades on the NASDAQ stock exchange.
Is Precigen Inc a Good Stock to Buy?
Determining whether Precigen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PGEN quote. (ISIN: US74017N1054)
What Is the Precigen Inc Stock Price Today?
The Precigen Inc stock price today is 4.080.
What Is the Stock Symbol for Precigen Inc?
The stock symbol for Precigen Inc is ""PGEN.""
What Stock Exchange Does Precigen Inc Trade On?
Precigen Inc is listed and trades on the NASDAQ stock exchange.
Is Precigen Inc a Good Stock to Buy?
Determining whether Precigen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PGEN quote. (ISIN: US74017N1054)
Fair Value
An estimate of a Precigen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.885
4.210
52 wk Range
0.651
5.225
PGEN Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
PGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Precigen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.8854.210
52 wk Range
0.6515.225
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Precigen's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
8.250
Upside
+102.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Precigen Inc Company Profile
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen Inc SWOT Analysis
Gene Therapy Pionee | Precigen's PRGN-2012 for RRP treatment nears FDA decision, potentially revolutionizing care for an expanded patient population of 27,000 in the U.S. |
Commercial Readiness | Explore Precigen's strategic preparations for PRGN-2012's launch, including manufacturing upgrades and targeted marketing to 500 key prescribers. |
Pipeline Potential | Delve into Precigen's diverse portfolio, featuring promising candidates like PRGN-2009 for cervical cancer and PRGN-3006 for AML, poised for pivotal trials. |
Financial Outlook | Analyst price targets range from $5 to $7, reflecting optimism about Precigen's extended cash runway and potential for breakthrough gene therapies. |
Precigen Inc Earnings Call Summary for Q4/2024
- Precigen reported a net loss of $126.2M for 2024, up from $95.9M in 2023, with stock rising 6.59% in aftermarket trading
- FDA accepted BLA for PRGN-2012 with priority review; company expects commercial revenues to begin in H2 2025
- Cash position at $97.9M end of 2024; company preparing for potential launch targeting 27,000 adult RRP patients in U.S.
- CEO Helen Sabzavari: "We are on the verge of commercializing our lead asset, PRGN-2012 in RRP"
- Risks include regulatory approval dependency, potential future competition, and financial sustainability amid continued losses
Last Updated: 19/03/2025, 22:46
Read Full TranscriptCompare PGEN to Peers and Sector
Metrics to compare | PGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.7x | −2.5x | −0.6x | |
PEG Ratio | −0.45 | −0.08 | 0.00 | |
Price/Book | −33.0x | 1.1x | 2.6x | |
Price / LTM Sales | 279.4x | 7.3x | 3.3x | |
Upside (Analyst Target) | 111.3% | 390.2% | 37.9% | |
Fair Value Upside | Unlock | 28.3% | 3.9% | Unlock |
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 8.250
(+102.21% Upside)
Earnings
Latest Release
Aug 13, 2025
EPS / Forecast
-0.09 / -0.0833
Revenue / Forecast
900.00K / 666.67K
People Also Watch
FAQ
What Stock Exchange Does Precigen Trade On?
Precigen is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Precigen?
The stock symbol for Precigen is "PGEN."
What Is the Precigen Market Cap?
As of today, Precigen market cap is 1.22B.
What Is Precigen's Earnings Per Share (TTM)?
The Precigen EPS (TTM) is -0.43.
When Is the Next Precigen Earnings Date?
Precigen will release its next earnings report on 11 Nov 2025.
From a Technical Analysis Perspective, Is PGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Precigen Stock Split?
Precigen has split 0 times.
How Many Employees Does Precigen Have?
Precigen has 143 employees.
What is the current trading status of Precigen (PGEN)?
As of 10 Sept 2025, Precigen (PGEN) is trading at a price of 4.080, with a previous close of 4.13. The stock has fluctuated within a day range of 3.885 to 4.210, while its 52-week range spans from 0.651 to 5.225.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.